[Edaily Reporter YU JIN-HEE ] Lameditech ( LAMEDITECH Co., Ltd.(462510)), a company specializing in laser beauty and medical devices, is entering the extracellular matrix (ECM) skin booster business, which has rapidly emerged as a new paradigm in the next-generation aesthetic medicine market. The company’s strategy is to combine its established core technology in precision micro-laser hardware with high-value-added bio-regenerative materials derived from the human body, aiming to directly overcome the limitations typically faced by late entrants to the market.

‘IO-FILL’ to Launch in Korea Next Month… Differentiated Safety Through Decellularization Process Using Natural Surfactants

According to industry sources on the 11th, LAMEDITECH Co., Ltd. will officially supply its new skin booster brand, “IO-FILL,” to the domestic hospital and clinic market next month. The company plans to take delivery of its first batch of products from Iretec Korea—a manufacturer specializing in allogeneic ECM with which it signed a domestic distribution agreement earlier this month—finalize the establishment of its distribution channels, and then begin expanding prescriptions in earnest.

Since autologous ECM is processed from human-derived tissue—such as that from post-mortem donors—it is strictly regulated as “human tissue” under the law, unlike general over-the-counter medical products or manufactured goods. To legally store, distribute, and supply human-derived materials, handling companies must secure specialized storage facilities and quality control systems that meet government standards, as well as a human tissue bank license.

Since September of last year, LAMEDITECH Co., Ltd. has been steadily building the infrastructure to establish a human tissue bank at its headquarters in Gasan-dong, Geumcheon-gu, Seoul, and in May of this year, it completed the process of obtaining formal approval from the Ministry of Food and Drug Safety. Through this, the company has proactively cleared the legal and regulatory hurdles required to enter the bio-regenerative medicine materials market.

The aspect that most distinctly sets IoPhil apart from existing competing products is its proprietary manufacturing process. During the decellularization stage—in which the epidermis and cells are removed from human skin tissue—the company applies a patented natural composite surfactant.

Existing allogeneic ECM products have extensively used chemically synthesized surfactants during the cell removal process. This method has consistently been criticized for the risk that microscopic chemical residues may remain even after post-processing washing, potentially causing unwanted side effects in patients—such as inflammatory reactions or tissue fibrosis—following procedures.

In contrast, IoPhil uses naturally derived surfactants to thoroughly remove immune rejection cells and impurities while preserving the inherent biocompatibility of the protein structure in its original form. In fact, comparative histological evaluations through preclinical animal studies showed significantly lower inflammation levels and fibrosis rates compared to synthetic surfactants, and the product has completed safety verification by demonstrating excellent tissue compatibility.

The reason LAMEDITECH Co., Ltd.’s entry into the ECM market is drawing industry attention is that the company has adopted an “integrated platform strategy” that goes beyond simply acting as a distributor, instead organically combining its proprietary laser hardware with the product.

The company plans to integrate IoFil with a professional-use fractional laser medical device currently undergoing product approval review by the Ministry of Food and Drug Safety. Fractional lasers create uniform microchannels on the skin’s surface while minimizing thermal damage to the epidermis.

When IoPhil is applied immediately after a laser treatment—while the skin barrier is still open—the penetration rate and uniformity of active ingredients into the deeper layers of the skin are dramatically improved compared to conventional intradermal injections or topical application methods.

The existing skin booster market began with first-generation hyaluronic acid (HA) injections, which physically filled lost volume. Subsequently, the focus shifted to second-generation products—such as polynucleotides (PN) extracted from salmon testicles and the synthetic polymer polylactic acid (PLLA)—that indirectly stimulate the skin’s own collagen synthesis.

Recently, the market has been rapidly shifting toward the third-generation ECM era, which goes beyond simple synthetic signaling to reconstruct the structure of the dermis itself to its original state. The ECM is the core support structure of human skin, composed of collagen, elastin, fibronectin, laminin, and hyaluronic acid. It receives overwhelmingly positive evaluations for its therapeutic efficacy and longevity, as it directly restores the skin’s supportive framework—which has deteriorated due to aging—using biocompatible materials.

According to the securities industry, the domestic ECM skin booster market is projected to grow at a steep annual average rate of over 300%, expanding from 9.9 billion won in 2025 to 92.5 billion won this year and 172.9 billion won next year. The penetration rate within the domestic skin booster market is also expected to rise from 3% last year to 28% next year.

LAMEDITECH Co., Ltd.’s strategy is to enter the market—established by leading biotech companies—with a turnkey solution that combines a device (DDS) and a material (IoPhil), thereby achieving clear differentiation from competitors.

Completion of the “Beauty Devices, Diagnostics, and Biotech” Trio… Annual Revenue Exceeds 15 Billion Won, Set for a Quantum Leap to 30 Billion Won Next Year

With this, LAMEDITECH Co., Ltd. completes a stable “triangle” portfolio encompassing its existing core business—the “PuraCell” line of aesthetic lasers—along with next-generation diagnostic healthcare devices and bio-ECM materials.

The “HandyRay-Glu,” a needle-free multi-functional medical device that recently received approval from the Ministry of Food and Drug Safety, will also play a key role in driving sales growth. HandyRay-Glu is an innovative device that uses ultra-compact laser technology to create micro-perforations in the skin for blood sampling and immediate blood glucose measurement—all without pain or the risk of secondary infection.

As a result, the company’s earnings growth is expected to accelerate further. LAMEDITECH Co., Ltd.’s annual revenue has followed a steep growth trajectory, rising from 1 billion won in 2021 to 2.1 billion won in 2022, 2.9 billion won in 2023, 6.6 billion won in 2024, and 7.2 billion won last year. This year, driven by strong exports of aesthetic devices and the commercialization of HandyRay Glue, the company is projecting sales of 15 billion won—more than double the previous year’s figure. Once sales of IoPhil begin in earnest next month and are fully reflected in next year’s annual results, a quantum leap to annual sales exceeding 30 billion won is highly likely.

The company is also accelerating the expansion of its overseas distribution network. By signing local distribution agreements focused on Shinhung aesthetic medicine markets such as Brazil and India, it has expanded its export channels to over 20 countries worldwide. Discussions are underway with Henry Schein, the world’s largest medical device distributor, regarding supply to the U.S. market, and the company plans to secure additional sales hubs in Europe and the Middle East by the end of the year.

LAMEDITECH Co., Ltd. official stated, “IoPhil is a product that fully meets the safety requirements of the aesthetic medicine field thanks to its high biocompatibility and patented natural decellularization process,” adding, “Armed with our unique converged platform—which integrates with laser equipment—we aim to leap forward as a global leader in regenerative medical aesthetics, joining the 100 billion won annual revenue club within the next five years.”